達勢股份(01405.HK)料去年淨虧損收窄至不高於2,900萬人幣
達勢股份(01405.HK)公布,預期去年總收益不少於30億元人民幣(下同),按年增長不少於48%;公司股權持有人應佔淨虧損不高於2,900萬元,2022年淨虧損約2.23億元;非國際財務報告準則經調整淨利潤不少於800萬元,2022年經調整淨虧損1.14億元。
公司指出,去年擴大門店網絡,門店總數由2022年12月31日的588家增加至去年12月31日的768家;去年現有門店的收益持續增長,而新增長市場的新店銷售表現強勁;去年門店層面及公司層級的營運效率均有所提高,進一步提升利潤率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.